Study S001619

A Dose Block-randomized, Double-blind, Placebo-controlled, Dose-escalating Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of SR Exenatide (PT302) After Subcutaneous Injection in Healthy Male Volunteers

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00964262
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: TRIPLE
Status: COMPLETED
Enrollment: 34
Start: 2009-08
Primary completion: 2010-10
Lead sponsor: Peptron, Inc.
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:SR Exenatide (PT302); DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

To evaluate the safety and pharmacokinetics of SR exenatide (PT302) in healthy subjects after a single subcutaneous injection [8 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023956	Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study. Gu N, Clinical therapeutics	2014	Randomized trial	PMID 24373998 DOI	cites ClinicalTrials.gov:NCT00964262; registry reference DERIVED:24373998